Cullinan Therapeutics, Inc.
CGEM
$7.17
-$0.19-2.52%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 9.09% | -7.00% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 37.82% | -0.09% | |||
| Operating Income | -37.82% | 0.09% | |||
| Income Before Tax | -44.44% | -2.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.44% | -1.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.44% | -1.79% | |||
| EBIT | -37.82% | 0.09% | |||
| EBITDA | -37.88% | 0.09% | |||
| EPS Basic | -44.17% | -1.23% | |||
| Normalized Basic EPS | -44.17% | -1.48% | |||
| EPS Diluted | -44.17% | -1.23% | |||
| Normalized Diluted EPS | -44.17% | -1.48% | |||
| Average Basic Shares Outstanding | 0.19% | 0.55% | |||
| Average Diluted Shares Outstanding | 0.19% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||